10-Q · April 30, 2026
PROCEPT BioRobotics recognized significant growth in Q1 2026, reporting revenues of $83.13 million, a 20% increase from $69.16 million in Q1 2025. Despite the growth in revenue, the company netted a loss of $31.64…
PRCT earnings analysis
10-Q · Filed November 4, 2026 · Our reading of the company's report
The latest report
PROCEPT delivered 18% year-over-year revenue growth to $98.291 million and approximately 22% procedure growth, with gross margin improving to approximately 66%. However, revenue missed the $100.427 million consensus…
Read full summary
PROCEPT delivered 18% year-over-year revenue growth to $98.291 million and approximately 22% procedure growth, with gross margin improving to approximately 66%. However, revenue missed the $100.427 million consensus estimate, EPS was negative $0.46 versus negative $0.39 expected, and net loss widened to $26.516 million. Management maintained full-year 2026 revenue guidance of $390 million to $410 million and an adjusted EBITDA loss outlook of $30 million to $35 million, producing a mixed overall read-through.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.46
- Gross margin
- 66%
What stood out
-
Revenue and procedure growth remained strong
Third-quarter revenue was $98.291 million, up 18% year over year, while procedure volume increased approximately 22%.
-
Gross margin improved year over year
Gross margin was approximately 66%, above the 64.8% reported in 2025 Q3 and broadly consistent with the 66.0% reported in 2026 Q2.
-
International and placement growth continued
International growth and system placements expanded during the quarter, supporting the 18% year-over-year revenue increase to $98.291 million.
-
Full-year outlook maintained
Full-year 2026 revenue guidance of $390 million to $410 million was reiterated, along with approximately 65% gross margin and 54,000 to 56,000 U.S. procedures.
What to watch
-
Quarterly revenue missed expectations
Revenue of $98.291 million was approximately $2.136 million below the $100.427 million consensus estimate, indicating near-term execution and demand-conversion risk.
-
Losses widened despite growth
Diluted EPS was negative $0.46 versus negative $0.39 expected, while net loss widened to $26.516 million despite 18% year-over-year revenue growth.
-
Profitability remains a key risk
The filing states that there were no material changes to previously disclosed risk factors during the nine months ended September 30, 2026; however, the reiterated outlook includes a $30 million to $35 million adjusted EBITDA loss, leaving continued profitability and cash-burn risk.
Management's outlook
Management reiterated full-year 2026 revenue guidance of $390 million to $410 million, approximately 65% gross margin, 54,000 to 56,000 U.S. procedures, and a $30 million to $35 million adjusted EBITDA loss.
Earlier filings 4
10-K · February 26, 2026
PROCEPT reported full-year revenue of $308.1 million for the year ended December 31, 2025, up from $224.5 million in 2024, driven by system placements and disposables, but continued to incur losses (net loss $95.6…
10-K · February 27, 2025
PROCEPT reported a strong revenue growth of 64.8% year-over-year, achieving $224.5 million in 2024, up from $136.2 million in 2023. However, the company is still incurring significant losses with a net loss of $91.4…
10-Q · October 28, 2024
PROCEPT reported Q3 revenue of $58.37M (up from $35.10M in Q3 2023 and up vs Q2 2024 ~$53.35M), driving gross profit of $36.91M and a gross margin of 63.2%. Operating loss narrowed to $(22.43)M and diluted loss per…
Smart money in PRCT
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every PRCT trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.